EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Vaccination with parasite-specific TcTASV proteins combined with recombinant baculovirus as a delivery platform protects against acute and chronic Trypanosoma cruzi infection

Yamil E Masip, Lucas D Caeiro, Maximiliano Cosenza, Miriam Postan, Guido Molina, Oscar Taboga, María Paula Molinari, Valeria Tekiel

Frontiers in Cellular and Infection Microbiology · 2024

DOI: 10.3389/fcimb.2024.1297321 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Yamil E Masip und 7 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigaciones Biotecnológicas, - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Parasites, Chagas Disease, Trypanosoma cruzi, Vaccines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Promoción Científica y Tecnológica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chagas’ is a neglected disease caused by the eukaryotic kinetoplastid parasite, Trypanosoma cruzi. Currently, approximately 8 million people are infected worldwide, most of whom are in the chronic phase of the disease, which involves cardiac, digestive, or neurologic manifestations. There is an urgent need for a vaccine because treatments are only effective in the initial phase of infection, which is generally underdiagnosed. The selection and combination of antigens, adjuvants, and delivery platforms for vaccine formulations should be designed to trigger mixed humoral and cellular immune responses, considering that T. cruzi has a complex life cycle with both intracellular and bloodstream circulating parasite stages in vertebrate hosts. Here, we report the effectiveness of vaccination with a T. cruzi -specific protein family (TcTASV), employing both recombinant proteins with aluminum hydroxide and a recombinant baculovirus displaying a TcTASV antigen at the capsid. Vaccination stimulated immunological responses by producing lytic antibodies and antigen-specific CD4+ and CD8+ IFNɣ secreting lymphocytes. More than 90% of vaccinated animals survived after lethal challenges with T. cruzi , whereas all control mice died before 30 days post-infection. Vaccination also induced a strong decrease in chronic tissue parasitism and generated immunological memory that allowed vaccinated and infected animals to control both the reactivation of the infection after immunosuppression and a second challenge with T. cruzi . Interestingly, inoculation with wild-type baculovirus partially protected the mice against T. cruzi . In brief, we demonstrated for the first time that the combination of the baculovirus platform and the TcTASV family provides effective protection against Trypanosoma cruz i, which is a promising vaccine for Chagas disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ParasitesChagas DiseaseTrypanosoma cruziVaccinesProtozoan VaccinesHumansAnimalsMiceBaculoviridaeAntigens, ProtozoanVaccination

Stichwörter der Autor:innen

Chagas’ diseaseTcTASVbaculovirusmultigene familytrypomastigotevaccine

Substanzen

Antigens, ProtozoanVaccinesProtozoan Vaccines

Autor:innen und Institutionen

  • Instituto de Investigaciones Biotecnológicas, - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
  • Escuela de Bio y Nanotecnologías (EByN), Universidad Nacional de San Martín (UNSAM), Buenos Aires, Argentina.
  • Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
  • Instituto de Agrobiotecnología y Biología Molecular (IABIMO), Instituto Nacional de Tecnología Agropecuaria (INTA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.

Förderung

  • Agencia Nacional de Promoción Científica y Tecnológica

Zitieren

APA

Masip, Y. E., Caeiro, L. D., Cosenza, M., Postan, M., Molina, G., Taboga, O., Molinari, M. P., & Tekiel, V. (2024). Vaccination with parasite-specific TcTASV proteins combined with recombinant baculovirus as a delivery platform protects against acute and chronic Trypanosoma cruzi infection. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1297321

Vancouver

Masip YE, Caeiro LD, Cosenza M, Postan M, Molina G, Taboga O, et al. Vaccination with parasite-specific TcTASV proteins combined with recombinant baculovirus as a delivery platform protects against acute and chronic Trypanosoma cruzi infection. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1297321

BibTeX
@article{Masip2024,
  author = {Masip, Yamil E and Caeiro, Lucas D and Cosenza, Maximiliano and Postan, Miriam and Molina, Guido and Taboga, Oscar and Molinari, María Paula and Tekiel, Valeria},
  title = {Vaccination with parasite-specific TcTASV proteins combined with recombinant baculovirus as a delivery platform protects against acute and chronic Trypanosoma cruzi infection},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2024},
  doi = {10.3389/fcimb.2024.1297321}
}
Kostenlos starten →